<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049100</url>
  </required_header>
  <id_info>
    <org_study_id>108771</org_study_id>
    <nct_id>NCT01049100</nct_id>
  </id_info>
  <brief_title>Surgical Staging in Cervical Cancer Prior to Chemoradiation</brief_title>
  <acronym>uterus11</acronym>
  <official_title>Prospective, Randomised and Multi-centric Therapy Optimisation Study for Examining the Influence of Surgical Staging on the Oncological Results for Patients With Cervix Carcinoma of the FIGO Stages IIB-IV After Chemoradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arbeitsgemeinschaft Radiologische Onkologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether the modified therapy on the basis of operative
      staging and systematic, pelvine and paraaortal lymphadenectomy for patients with cervical
      cancer of the FIGO stages IIB-IV prior to introducing radio-chemotherapy leads to a
      significant improvement of disease-free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to determine whether the modified therapy on the basis of operative
      staging and systematic, pelvine and paraaortal lymphadenectomy for patients with cervical
      cancer of the FIGO stages IIB-IV prior to introducing radio-chemotherapy leads to a
      significant improvement of disease-free survival.

      To this end, 250 patients with histologically verified cancer of the cervix uteri of the
      stages IIB-IV shall be randomised to a standard arm (ARM B), whereby the therapy shall be
      conducted on the basis of the clinical FIGO stage.

      The patients randomised to the test arm (Arm A), after determining the clinical FIGO stage,
      shall initially receive an operative staging in the form of a pelvine paraaortal
      lymphadenectomy (laparoscopic or open). On the basis of the operatively obtained findings, a
      (&quot;surgically&quot;) modified tumour stage shall be determined. This &quot;surgical&quot; tumour stage, which
      shall take into account the affection of the lymph nodes, the infiltration of the
      neighbouring organs and the intraperitoneal spread, shall serve as the basis for the
      execution of primary, combined radio-chemotherapy. The primary end-point is the disease-free
      survival of both groups, the secondary endpoints are overall survival, the local control of
      both groups, as well as the determination of toxicity and the quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS (disease-free survival)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS, LC, QOL (overall survival, local control,quality of life, the determination of toxicity)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>operative staging (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>operative staging and systemic lymphadenectomy, paraaortal and pelvine, laparoscopic or open</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard (B)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No surgical intervention. Clinical Staging (FIGO) CT Abdomen / pelvic enlarged or suspicious lymphnodes--&gt; CT controlled biopsy and histological analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lymphadenectomy</intervention_name>
    <description>paraaortal and pelvic lymphadenectomy laparoscopic or open</description>
    <arm_group_label>operative staging (A)</arm_group_label>
    <other_name>debulking, surgical staging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Staging</intervention_name>
    <description>clinical Staging (FIGO) (examination in narcosis, biopsy, cystoscopy, rectoscopy) X-Ray Radiograph of Thorax, Ultrasound of abdomen, CT abdomen / pelvis positive, suspicious lymphnodes--&gt; CT controlled biopsy</description>
    <arm_group_label>Standard (B)</arm_group_label>
    <other_name>FIGO Staging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Karnofsky-Index =/&gt; 70,

          -  age between 18 - 70 years

          -  histological assured cervical cancer (by biopsy)

          -  FIGO stages II B - IV

          -  written informed consent

          -  patient's ability to cooperate

        Exclusion Criteria:

          -  neuroendocrine tumors or histological mixed types containing neuroendocrine fractions

          -  pregnancy, lactation,

          -  distant metastases, except paraaortal metastases

          -  other malignant diseases in anamnesis

          -  pelvic radiotherapy in anamnesis

          -  severe internal diseases

          -  psychiatric diseases which might query the trial attendance or follow-up

          -  HIV-Infection or AIDS

          -  drug addiction

          -  existing motoric or sensoric polyneuropathy &gt; CTC Grad 1
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simone Marnitz, PD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Radiooncology (Charité Campus Mitte und Virchow), Charitéplatz 1, 10117 Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christhardt Köhler, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Gynaecology (Charité Campus Mitte und Benjamin Franklin), Charitéplatz 1, 10117 Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anja Dittgen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gynaecology (Charité Campus Mitte), Charitéplatz 1, 10117 Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simone Marnitz, PD</last_name>
    <phone>004930450627162</phone>
    <email>simone.marnitz@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Gynaecology, Charité Campus Mitte und Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christhardt Köhler, Professor</last_name>
      <phone>004930450564091</phone>
      <email>christhardt.koehler@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Anja Dittgen</last_name>
      <phone>004930450664434</phone>
      <email>anja.dittgen@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Christhardt Köhler, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anja Dittgen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology, Charité Campus Mitte und Campus Virchow</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Marnitz, PD</last_name>
      <phone>004930450527162</phone>
      <email>simone.marnitz@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Anja Dittgen</last_name>
      <phone>004930450664434</phone>
      <email>anja.dittgen@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Simone Marnitz, PD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anja Dittgen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ago.de</url>
    <description>Websites of the Association of Gynecological Cancer and Society of Radiooncology, Germany</description>
  </link>
  <link>
    <url>http://www.degro.org</url>
    <description>Association for Radiooncology</description>
  </link>
  <reference>
    <citation>Sakuragi N. Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer. Int J Clin Oncol. 2007 Jun;12(3):165-75. Epub 2007 Jun 27. Review.</citation>
    <PMID>17566838</PMID>
  </reference>
  <reference>
    <citation>Subak LL, Hricak H, Powell CB, Azizi L, Stern JL. Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstet Gynecol. 1995 Jul;86(1):43-50. Review.</citation>
    <PMID>7784021</PMID>
  </reference>
  <reference>
    <citation>Marnitz S, Köhler C, Roth C, Füller J, Bischoff A, Wendt T, Schneider A, Budach V. Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging. Strahlenther Onkol. 2007 Sep;183(9):473-8.</citation>
    <PMID>17762920</PMID>
  </reference>
  <reference>
    <citation>Bye A, Tropé C, Loge JH, Hjermstad M, Kaasa S. Health-related quality of life and occurrence of intestinal side effects after pelvic radiotherapy--evaluation of long-term effects of diagnosis and treatment. Acta Oncol. 2000;39(2):173-80.</citation>
    <PMID>10859007</PMID>
  </reference>
  <reference>
    <citation>Nag S, Erickson B, Thomadsen B, Orton C, Demanes JD, Petereit D. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):201-11.</citation>
    <PMID>10924990</PMID>
  </reference>
  <reference>
    <citation>Lai CH, Huang KG, Hong JH, Lee CL, Chou HH, Chang TC, Hsueh S, Huang HJ, Ng KK, Tsai CS. Randomized trial of surgical staging (extraperitoneal or laparoscopic) versus clinical staging in locally advanced cervical cancer. Gynecol Oncol. 2003 Apr;89(1):160-7.</citation>
    <PMID>12694671</PMID>
  </reference>
  <reference>
    <citation>Denschlag D, Gabriel B, Mueller-Lantzsch C, Tempfer C, Henne K, Gitsch G, Hasenburg A. Evaluation of patients after extraperitoneal lymph node dissection for cervical cancer. Gynecol Oncol. 2005 Mar;96(3):658-64.</citation>
    <PMID>15721408</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <last_update_submitted>January 14, 2010</last_update_submitted>
  <last_update_submitted_qc>January 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>PD Dr. med. Simone Marnitz / Prof. Dr. med. Christhardt Köhler</name_title>
    <organization>Department of Radiooncology (Charité Campus Mitte und Virchow) / Department of Gynaecology (Charité Campus Mitte und Benjamin Franklin)</organization>
  </responsible_party>
  <keyword>Surgical Staging</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Chemoradiation</keyword>
  <keyword>Outcome</keyword>
  <keyword>Toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

